Histamine releasing anesthetic drugs and muscle relaxants and their anesthetic importance
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Loading Image
Finding Sources
Finding Sources
I now have comprehensive data to write a thorough answer. Let me compile everything.
Histamine-Releasing Anesthetic Drugs and Muscle Relaxants: Anesthetic Importance
Histamine release during anesthesia is a clinically relevant phenomenon that can cause bronchospasm, cutaneous flushing, urticaria, hypotension, and - in severe cases - anaphylactoid reactions. The mechanism is typically a direct mast cell degranulation (non-IgE-mediated), not true anaphylaxis, though IgE-mediated reactions can also occur.
Mechanism of Histamine Release
Most drug-induced histamine release in anesthesia is a direct pharmacological action on mast cells rather than IgE-mediated anaphylaxis. This is dose-dependent, rate-dependent (faster injection = higher peak plasma levels = more release), and exhibits tachyphylaxis - a subsequent dose of the same size usually causes little to no further release.
"Histamine release typically is a direct action of the muscle relaxant on the mast cell rather than anaphylaxis mediated by immunoglobulin E." - Goodman & Gilman's, p. 261
Part I: Histamine-Releasing Anesthetic Drugs
1. Opioids
| Drug | Histamine Release | Clinical Significance |
|---|---|---|
| Morphine | Significant | Hypotension, urticaria, flushing, pruritus |
| Meperidine (pethidine) | Moderate | Hypotension, skin effects |
| Codeine | Moderate | Flushing, urticaria |
| Fentanyl | None/negligible | Preferred in hemodynamically compromised patients |
| Sufentanil | None | High-dose cardiac anesthesia |
| Remifentanil | None | - |
Morphine and meperidine release histamine through a non-immunological mechanism acting directly on cutaneous and systemic mast cells. Bolus IV dosing produces the worst effects - particularly hypotension from peripheral vasodilation and venodilation. Pruritus from opioids also has a central (spinal cord) component, so it is not entirely prevented by antihistamines.
Clinical importance: Meperidine and morphine should be avoided if possible in patients with reactive airways disease (e.g., asthma) and in patients with carcinoid syndrome. Synthetic opioids (fentanyl, sufentanil, remifentanil, alfentanil) do not release histamine and are preferred for cardiac surgery and high-risk patients.
"Bolus doses of meperidine, hydromorphone, and morphine evoke varying amounts of histamine release that can lead to profound drops in systemic vascular resistance and arterial blood pressure. The potential hazards of histamine release can be minimized by infusing opioids slowly or by pretreatment with H1 and H2 antagonists." - Morgan & Mikhail's Clinical Anesthesiology, 7e, p. 356
2. Intravenous Induction Agents
| Drug | Histamine Release |
|---|---|
| Thiopental (barbiturates) | Yes - from mast cells |
| Propofol | Minimal/rare |
| Etomidate | None |
| Ketamine | None |
Thiopental and barbiturates cause histamine release from mast cells and produce a higher incidence of wheezing in asthmatic patients compared to propofol. This is a key reason thiopental is contraindicated in asthmatic patients undergoing RSI - ketamine or propofol is preferred instead.
Propofol can theoretically cause histamine release but in practice has a much lower incidence of bronchospasm and is generally preferred over thiopental in reactive airways disease.
Etomidate does not release histamine, making it useful in hemodynamically unstable patients, though it provides relatively light anesthesia alone.
"Compared to propofol, barbiturates produce a higher incidence of wheezing in asthmatics, attributed to histamine release from mast cells during induction of anesthesia." - Goodman & Gilman's
"Thiopental should not be used in these patients [hemodynamically stable patients with severe bronchospasm] because it provokes release of histamine and can induce bronchospasm." - Roberts and Hedges' Clinical Procedures in Emergency Medicine
Part II: Histamine-Releasing Muscle Relaxants
Classification by Chemical Structure
The tendency to release histamine is strongly correlated with chemical class:
- Benzylisoquinoliniums - tend to release histamine (direct mast cell effect)
- Steroidal (aminosteroid) compounds - do NOT release histamine
Summary Table (from Morgan & Mikhail's / Katzung's)
| Drug | Class | Histamine Release | Autonomic Effects |
|---|---|---|---|
| d-Tubocurarine (dTc) | Benzylisoquinolinium | Marked (+++); also ganglionic blockade | Ganglionic block |
| Atracurium | Benzylisoquinolinium | Slight (+) | None |
| Mivacurium | Benzylisoquinolinium | Slight (similar to atracurium) | None |
| Cisatracurium | Benzylisoquinolinium | None/minimal (0) | None |
| Succinylcholine | Depolarizing | Slight | Muscarinic + ganglionic stimulation |
| Pancuronium | Steroidal | None (0) | Vagolytic (tachycardia) |
| Vecuronium | Steroidal | None (0) | None |
| Rocuronium | Steroidal | None (0) | Slight vagolytic |
| Gantacurium | Chlorofumarate | Slight (+) | None |
Individual Drug Details
d-Tubocurarine (historically most important)
The most potent histamine releaser among all available muscle relaxants. It causes hypotension by two mechanisms: (1) histamine release causing vasodilation, and (2) ganglionic blockade reducing sympathetic reflexes. The cardiovascular response to dTc is prevented by both antihistamines and by NSAIDs (aspirin), as the final step in dTc-induced hypotension is modulated by vasodilatory prostaglandins. Now largely withdrawn from clinical use.
Atracurium
Releases histamine at doses >0.4 mg/kg (rapid bolus). The safety margin for histamine release is approximately 3x greater than for dTc. Hypotension from atracurium is purely from histamine release (no ganglionic block). Slower injection rates markedly reduce this effect. A metabolite, laudanosine, has potential epileptogenic properties at high doses, though clinically insignificant at standard doses.
Mivacurium
Releases histamine to approximately the same degree as atracurium. Doses >0.15 mg/kg given as a rapid bolus cause transient hypotension. Main advantage is its ultra-short duration (20-30 min) due to hydrolysis by plasma pseudocholinesterase. Metabolism may be prolonged in severe liver disease (reduced pseudocholinesterase).
Cisatracurium
A stereoisomer of atracurium with 4x the potency but no histamine release. This demonstrates that histamine release is stereospecific. It is metabolized by Hofmann elimination and produces less laudanosine. It is now preferred over atracurium in situations where histamine release is undesirable (e.g., asthma, ICU use).
"It is approximately four times as potent as atracurium, and in contrast to atracurium, it does not cause histamine release, thus indicating that histamine release may be stereospecific." - Miller's Anesthesia, 10e
Succinylcholine (suxamethonium)
The only depolarizing agent in clinical use. It causes slight histamine release and also stimulates both autonomic ganglia and cardiac muscarinic receptors (can cause bradycardia, especially with a second dose). Succinylcholine releases histamine but to a lesser extent than tubocurarine unless administered rapidly.
Part III: Clinical Effects of Histamine Release
When plasma histamine concentrations rise, a cascade of dose-related effects occurs:
| Plasma Histamine Concentration | Effects |
|---|---|
| Mild elevation | Skin flushing, urticaria along vein of injection |
| Moderate elevation | Hypotension (peripheral vasodilation), tachycardia, bronchospasm |
| Severe elevation | Anaphylactoid/anaphylactic reaction, cardiovascular collapse |
H1 receptor effects: Bronchospasm, increased mucus secretion, vasodilation, urticaria, pruritus
H2 receptor effects: Increased gastric acid, vasodilation, tachycardia
Combined H1+H2 stimulation: Maximal hypotension
Part IV: Anesthetic Importance and Management
High-Risk Scenarios
- Asthma / reactive airways disease - any histamine-releasing drug can precipitate severe bronchospasm
- Hemodynamic instability - histamine-mediated vasodilation worsens hypotension
- Neurosurgery - histamine causes cerebral vasodilation, raises ICP and lowers CPP
- Carcinoid syndrome - avoid all agents that may trigger vasoactive mediator release
- Pregnancy/obstetrics - morphine and meperidine advised against when possible
Drug Selection Strategy
- Avoid morphine/meperidine in asthmatics; use fentanyl/remifentanil
- Avoid thiopental in reactive airways; use ketamine or propofol for induction
- Avoid atracurium/mivacurium in asthmatics or neurologically compromised patients; prefer cisatracurium, vecuronium, or rocuronium
- Steroidal muscle relaxants (vecuronium, rocuronium, cisatracurium) are the safest choices when histamine release is a concern
Prevention Strategies
- Slow injection rate - most effective intervention (reduces peak plasma concentration)
- H1 + H2 antihistamine pretreatment (e.g., diphenhydramine + ranitidine/famotidine) - combination is more effective than either alone
- Dilute the drug before administration
- Use alternative drugs without histamine-releasing potential
Treatment of Histamine Release
- IV fluids and vasopressors for hypotension
- Bronchodilators (salbutamol/albuterol) for bronchospasm
- H1 antihistamines (IV diphenhydramine)
- H2 antihistamines
- Corticosteroids for severe reactions
- Epinephrine for anaphylaxis/anaphylactoid reactions
Summary: Mivacurium Dose-Response to Histamine Release
The graph below (from Miller's Anesthesia) demonstrates the dose-dependent cardiovascular effects of mivacurium - note how mean arterial pressure drops significantly with doses of 0.20 mg/kg and above (fast injection), while heart rate is relatively preserved:
With fast injection, a 15-20% decrease in arterial pressure occurs at 2.5-3 times the ED95 (0.20-0.25 mg/kg); with slower injection over 30 seconds, changes are less than 10%. - Miller's Anesthesia, 10e
Key Takeaways
- Benzylisoquinoliniums release histamine; aminosteroids do not - this is the most tested concept
- dTc > atracurium = mivacurium > cisatracurium in terms of histamine-releasing potency among NMBDs
- Morphine > meperidine > codeine among opioids; synthetic opioids (fentanyl, sufentanil) release none
- Thiopental releases histamine from mast cells - avoid in asthma
- Cisatracurium is preferred over atracurium because it has the same Hofmann elimination but with no histamine release
- Slow injection rate + H1/H2 pretreatment are the key preventive strategies
- Histamine release shows tachyphylaxis - subsequent identical doses cause far less effect
Sources:
- Morgan & Mikhail's Clinical Anesthesiology, 7e - Chapters 10, 11
- Miller's Anesthesia, 10e - Chapters 24, 3
- Goodman & Gilman's Pharmacological Basis of Therapeutics - Chapters 4, 7
- Katzung's Basic and Clinical Pharmacology, 16e - Chapter 27
Reading File
Running Command
Reading File
Running Command
Writing File
Running Command
Your PDF is ready:
Histamine Releasing Drugs Anesthesia
PDF Document · PDF
The document includes:
- Overview and mechanism of histamine release (non-IgE mast cell degranulation)
- Receptor effects table (H1, H2, combined)
- Opioid comparison table - morphine/meperidine vs. synthetic opioids
- IV induction agents - thiopental vs. propofol/etomidate/ketamine
- Full muscle relaxant table with class, histamine potency, autonomic effects, and anesthetic notes
- Mivacurium dose-response graph (from Miller's Anesthesia)
- Neurosurgery impact - ICP/CPP effects
- High-risk clinical scenarios with drugs to avoid and preferred alternatives
- Prevention and treatment tables
- 8 key exam pearls
You can use different colors for pdf rather than a single uniform colour throughout the pdf..save this
Reading File
Reading File
Editing File
Saved. Your preference has been updated. From now on, every PDF I generate will use a rotating color palette across sections - each major section heading (H1) gets a different color band, sub-headings coordinate with their parent section's color, and table headers match the section palette too.
The color rotation will follow a scheme like:
- Section 1 - Deep blue
#1a3a5c - Section 2 - Teal
#0f6b6b - Section 3 - Purple
#4a2a6b - Section 4 - Dark green
#1a5c2a - Section 5 - Dark red
#7a1a1a - Section 6 - Navy
#0d2b5c - Section 7 - Charcoal teal
#1a4a4a - ...and so on, cycling through
Would you like me to regenerate the histamine PDF right now with this multi-color scheme applied?
This is a shared conversation. Sign in to Orris to start your own chat.